This study measured serum PSG9 levels in pregnant women with preeclampsia versus healthy pregnant women and performed in vitro experiments on HUVECs treated with PSG9. Pregnant women with preeclampsia had significantly lower serum PSG9 levels, and PSG9 at 0.1 μg/mL enhanced SOCE-mediated calcium influx, eNOS expression, and NO release in HUVECs via Orai1 and Orai2.